{"id":"W2345491145","doi":"10.1182/blood.v124.21.4542.4542","title":"Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nilotinib; Internal medicine; Interim analysis; Adverse effect; Clinical endpoint; Anemia; Myeloid leukemia; Clinical trial; Imatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004983924,0.000812923,0.001413709,0.0002992367,0.0003309626,0.0009131464,0.0006574143,0.0005647899,0.001503637],"category_scores_gemma":[0.001793219,0.0002905312,0.001843959,0.0003331123,0.0004714994,0.0007737745,0.0005345219,0.001368497,0.0003817811],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009330715,"about_ca_system_score_gemma":0.0009123511,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003509675,"about_ca_topic_score_gemma":0.0007103826,"domain_scores_codex":[0.9986989,0.0007221577,0.00009166043,0.0001736908,0.0001334298,0.000180072],"domain_scores_gemma":[0.9985668,0.000317589,0.000481682,0.0002567459,0.0001063407,0.000270936],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7589588,0.0140229,0.131187,0.0003832384,0.004674932,0.0003466189,0.0002268985,0.01285012,0.01915449,0.0003338383,0.002718455,0.05514277],"study_design_scores_gemma":[0.1018124,0.5128631,0.3312858,0.00007439956,0.006043597,0.001137707,0.0002207209,0.01427018,0.02127549,0.0007495435,0.01013206,0.0001350129],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996139,0.000357901,0.0006123671,0.00008540749,0.00001611962,0.0004773213,0.001461796,0.00002925056,0.0008207451],"genre_scores_gemma":[0.9936241,0.0001141318,0.001097875,0.0001432682,0.00002494688,0.0005080821,0.003701434,0.00001076993,0.0007753269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004983924,"threshold_uncertainty_score":0.02635777,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009825242666280267,"score_gpt":0.2629183527303013,"score_spread":0.2530931100640211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}